List of Excipients in Branded Drug DESYREL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	CELLULOSE, MICROCRYSTALLINE
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	HYPROMELLOSE
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	LACTOSE MONOHYDRATE
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	MAGNESIUM STEARATE
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	POLYETHYLENE GLYCOL
Pragma Pharmaceuticals LLC	DESYREL	trazodone hydrochloride	58463-005	POVIDONE

Desyrel Excipient Strategy and Commercial Opportunities for Trazodone

Last updated: August 2, 2026

Desyrel is the original brand associated with trazodone hydrochloride, an older serotonin-modulating antidepressant now supplied primarily through generic trazodone products. The active ingredient has limited remaining composition-of-matter value, so commercial differentiation depends on dosage form, excipient selection, manufacturability, patient adherence, and regulatory positioning.

The strongest opportunities are low-cost tablet optimization, lactose-free and swallow-friendly products, orally disintegrating or rapidly dispersing formulations, liquid dosage forms, and modified-release products. Any differentiated formulation must address trazodone’s high dose, bitter taste, dose-related sedation, tablet burden, and potential for rapid-release tolerability issues.

What is Desyrel and how is trazodone commercially positioned?

Desyrel contains trazodone hydrochloride, an oral serotonin antagonist and reuptake inhibitor approved for major depressive disorder. Trazodone is also widely prescribed off label for insomnia, although insomnia is not the primary FDA-approved indication for Desyrel or generic trazodone tablets. The original brand has largely been displaced by generic products.

Attribute	Commercial position
Brand	Desyrel
Active ingredient	Trazodone hydrochloride
Therapeutic class	Serotonin antagonist and reuptake inhibitor
Primary FDA indication	Major depressive disorder
Common tablet strengths	50 mg, 100 mg, 150 mg
Typical dosage form	Immediate-release oral tablet
Generic status	Broad generic availability
Main commercial constraint	Mature active ingredient and low-cost generic competition
Main differentiation routes	Formulation, convenience, tolerability, packaging, and supply reliability

The commercial market is price-sensitive. A new product is unlikely to compete successfully through an ordinary immediate-release tablet alone unless it provides lower manufacturing cost, improved supply continuity, a meaningful excipient attribute, or a differentiated dosage form.

What excipients are used in Desyrel and generic trazodone tablets?

Desyrel and generic trazodone immediate-release tablets generally use conventional solid-dose excipients. FDA labeling identifies excipient classes that can include lactose, microcrystalline cellulose, starch-based disintegrants, magnesium stearate, and colloidal silicon dioxide, although the precise composition can vary by strength and manufacturer.[1]

Excipient class	Typical function	Strategic relevance
Lactose monohydrate	Diluent and compression aid	Low cost, but creates a lactose-intolerance and labeling consideration
Microcrystalline cellulose	Filler, dry binder, and compression aid	Supports robust direct compression
Pregelatinized starch or starch	Binder and filler	Can improve compactability and tablet structure
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup
Crospovidone	Alternative superdisintegrant	May support faster or more reproducible disintegration
Magnesium stearate	Lubricant	Necessary for ejection but can impair wetting at excessive levels
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and die filling
Film-coating polymers	Protection, appearance, swallowability	Can support moisture protection and taste reduction
Opacifiers and colorants	Product identification	Useful for strength differentiation and medication-error reduction

The exact qualitative and quantitative formula must be confirmed against the applicable product label and regulatory filing. Generic formulations are not required to use the same excipients unless an ANDA strategy seeks pharmaceutical equivalence under the applicable FDA framework.

Which excipient problems matter most for trazodone tablets?

High-dose tablet burden

Trazodone is commonly administered at doses that are materially larger than many modern antidepressants. A single dose may require one or more tablets, particularly when lower-strength tablets are used for titration or bedtime dosing. This creates an opportunity for high-load formulations with improved tablet hardness, reduced tablet weight, and better swallowability.

A formulation developer should prioritize:

• High drug loading.
• Low tablet mass.
• Adequate tensile strength.
• Rapid disintegration.
• Low friability.
• Robust content uniformity.
• Compatibility with score lines where dose splitting is claimed.

Microcrystalline cellulose, anhydrous dibasic calcium phosphate, spray-dried mannitol, and optimized starch systems can be evaluated as alternatives or partial substitutes for lactose. Calcium phosphate may improve mechanical strength but can alter disintegration and may complicate dissolution optimization.

Bitter taste

Trazodone hydrochloride is a strong candidate for taste-masking work because an orally disintegrating tablet, oral granule, or liquid product may expose the active ingredient to the oral cavity. Conventional film coating can reduce incidental taste exposure but may not provide adequate masking after tablet dispersion.

Potential strategies include:

• Polymer-coated drug particles.
• Ion-exchange resin complexes.
• Lipid or wax barriers.
• pH-dependent polymer coatings.
• Multiparticulate encapsulation.
• Flavor systems combined with high-efficiency sweeteners.
• Rapid-swallow formulations that minimize residence time in the mouth.

Taste masking is commercially relevant for patients with dysphagia, geriatric patients, and products intended for use without water. It also creates a formulation distinction that is more defensible than simply changing a filler.

Sedation and dose flexibility

Trazodone is frequently used at lower doses for sleep-related prescribing, despite its FDA-approved antidepressant indication. Lower-strength products and flexible dose delivery can therefore have commercial value. Excipient selection alone will not remove trazodone’s pharmacologic sedation, but a formulation may improve titration and reduce accidental overexposure caused by poor dose splitting.

A product intended for dose flexibility should evaluate:

• Score-line performance.
• Uniformity of split tablets.
• Low-dose content uniformity.
• Packaging that separates strengths clearly.
• Modified-release behavior if the formulation is intended to reduce peak exposure.

Any claim that a formulation reduces sedation or improves next-day functioning would require clinical support and cannot be inferred from excipient selection.

What formulation opportunities exist for Desyrel and trazodone?

Lactose-free immediate-release tablets

A lactose-free product is the most accessible excipient-led opportunity. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipient systems.

Commercial advantages include:

• Broader patient acceptability.
• Simplified excipient messaging.
• Potential suitability for customers avoiding lactose-derived ingredients.
• A differentiated product description without requiring a new active ingredient.

The opportunity is limited if generic competitors already market lactose-free trazodone. The commercial value must therefore be supported by reliable supply, competitive pricing, or a clearly communicated formulation attribute.

Orally disintegrating tablets

An orally disintegrating tablet could address swallowing difficulty and administration without water. The principal technical barriers are dose load, taste, mechanical weakness, friability, and moisture sensitivity.

Likely excipient systems include:

• Mannitol for mouthfeel and rapid dissolution.
• Crospovidone or sodium starch glycolate for disintegration.
• Low-substituted hydroxypropyl cellulose for wicking and structure.
• Co-processed excipients for direct compression.
• Flavor and sweetener systems.
• Moisture-barrier packaging.

Because trazodone doses can be high, a true ODT may require multiple units or a larger tablet. A rapidly dispersing, swallowable tablet may be more commercially practical than a strict ODT meeting the FDA’s disintegration framework.

Oral solution or suspension

A liquid product can support dose titration, patients with dysphagia, and institutional use. Trazodone hydrochloride’s solubility, pH stability, taste, preservative compatibility, and container-closure performance would determine feasibility.

Excipient considerations include:

• Buffer selection.
• Sweeteners and flavorants.
• Preservatives.
• Suspending agents if a suspension is used.
• Chelating agents.
• Antioxidants where justified.
• Low-sorption packaging.
• Child-resistant and unit-dose delivery systems.

An oral solution may have a stronger differentiation profile than a new conventional tablet, but it carries higher stability, microbial-control, dosing-device, and packaging burdens.

Modified-release tablets

Modified release is the most technically differentiated opportunity. A prolonged-release formulation could seek to control peak concentration, reduce dosing frequency, or improve overnight exposure. The commercial case depends on clinical pharmacology rather than excipient novelty alone.

Candidate technologies include:

• Hydrophilic matrix tablets using hypromellose.
• Insoluble matrix systems.
• Coated multiparticulates.
• Osmotic delivery.
• Gastroretentive systems.
• Pulsatile or delayed-release systems.

A modified-release trazodone product would usually require a new drug application pathway, often a 505(b)(2) application if it relies partly on published literature or an approved reference product. FDA would generally expect comparative pharmacokinetic work and may require clinical evidence for a new dosing regimen or therapeutic claim.[2]

Film-coated and swallow-optimized tablets

The lowest-risk reformulation is a film-coated tablet optimized for swallowability, moisture protection, and strength identification. A smooth low-friction coating can reduce patient complaints without materially changing release.

Relevant coating components include:

• Hypromellose or polyvinyl alcohol.
• Polyethylene glycol plasticizer.
• Titanium dioxide or alternative opacifier where permitted.
• Iron oxides or other permitted colorants.
• Polymers selected for moisture resistance.

This strategy has modest regulatory complexity but limited exclusivity value. It is best suited to a low-cost generic or contract-manufacturing platform.

What regulatory pathway applies to a new Desyrel formulation?

The pathway depends on whether the product remains pharmaceutically equivalent to an approved immediate-release reference product.

Product concept	Likely pathway	Main development requirement
Same-strength immediate-release tablet	ANDA under section 505(j)	Pharmaceutical equivalence and bioequivalence
Lactose-free tablet with same release profile	Usually ANDA if other requirements are met	Formulation, bioequivalence, labeling, stability
New oral solution	ANDA only if a suitable reference and equivalence approach are available; otherwise 505(b)(2) may be relevant	PK, stability, dose-measuring device, microbiology
Orally disintegrating tablet	ANDA or 505(b)(2), depending on equivalence	Disintegration, dissolution, taste, bioequivalence
Modified-release product	Usually 505(b)(2) or another NDA-based route	Comparative PK and potentially clinical evidence
New indication	NDA or 505(b)(2)	Efficacy and safety evidence for the proposed indication
Combination with another active	NDA or 505(b)(2)	Combination rationale and clinical support

An excipient change does not automatically create a new regulatory product. If the formulation remains pharmaceutically equivalent and bioequivalent, an ANDA may remain possible. A new release mechanism, dosage form, strength, route, or labeling claim can move the program into a 505(b)(2) or NDA framework.[2]

What patents protect Desyrel and generic trazodone?

The original trazodone compound and conventional immediate-release tablet technology are mature. The commercial value of Desyrel is therefore not expected to depend on a live, broad composition-of-matter patent. Current patent risk is more likely to arise from formulation-specific, method-of-use, manufacturing, or packaging patents associated with particular products rather than from the basic trazodone molecule.

IP category	Expected relevance to trazodone
Original compound patent	Historical; likely expired
Conventional immediate-release tablet	Low barrier because of mature generic technology
Modified-release formulation	Potentially significant if claims are narrow and technically supported
Taste-masked particles	Potentially protectable through composition and process claims
ODT formulation	Potentially protectable, but crowded excipient prior art is a constraint
Method of use	Possible for specific dosing regimens or patient populations
Manufacturing process	Potentially useful for cost, impurity control, or scale-up
Packaging and dosing device	Narrow protection, but commercially useful
Trade secrets	Important for coating parameters, granulation, and scale-up

The Orange Book should be checked for the specific reference product and any listed patents or exclusivity. A generic applicant must also assess Paragraph IV exposure where listed patents cover the reference product or its approved uses.[3] Because trazodone products are old and widely genericized, the more material risk may be non-Orange Book patent rights covering a differentiated formulation.

When does Desyrel lose exclusivity?

Desyrel’s core market exclusivity has already lapsed. Trazodone has been available generically for decades, and ordinary immediate-release tablets face established competition. FDA’s Orange Book remains the controlling source for current patent listings, reference-product status, and any product-specific exclusivity.[3]

The practical exclusivity timeline is:

Period	Commercial implication
Original approval period	Brand commercialization and initial regulatory protection
Post-patent period	Generic entry and price erosion
Current market	Mature generic competition
Future differentiated product	Potential product-specific protection through formulation, use, or delivery claims

A new formulation would not inherit Desyrel’s historical exclusivity. It would need its own regulatory basis and patent strategy.

Are Paragraph IV challenges and generic litigation material?

Paragraph IV litigation is most relevant where a branded or 505(b)(2) trazodone product lists patents in the Orange Book. A conventional Desyrel-style immediate-release product is less likely to support a durable patent barrier because the active ingredient, dosage form, and release profile are mature.

Potential litigation triggers include:

• A Paragraph IV certification against listed formulation patents.
• A suit under the Hatch-Waxman framework after notice of a Paragraph IV certification.
• Patent disputes over modified-release technology.
• Litigation over method-of-use claims.
• Trade-secret disputes involving coating or manufacturing processes.
• Patent litigation involving a 505(b)(2) product and its relied-upon reference product.

The litigation risk for a new formulation depends on claim scope, prosecution history, enablement, written description, obviousness, and whether the formulation provides a measurable technical advantage. A patent that claims only routine substitution of one common filler for another is generally weaker than a patent tied to a defined dissolution profile, particle architecture, stability improvement, or clinically meaningful exposure profile.

How strong is the patent estate for a trazodone excipient strategy?

A conventional excipient program has low-to-moderate patent strength. Most common excipients are old, and broad claims covering lactose replacement, standard disintegrants, or ordinary film coatings are vulnerable to prior art and obviousness challenges.

A stronger patent estate would combine:

1. A defined formulation composition.
2. Narrow excipient ratios or particle attributes.
3. A reproducible manufacturing process.
4. A dissolution or pharmacokinetic limitation.
5. A clinically relevant use or adherence benefit.
6. Multiple claim types covering composition, process, dosage form, and use.

Potential claim targets include:

• Trazodone particles coated with a specified polymer layer.
• A high-drug-load tablet meeting defined hardness and disintegration limits.
• A modified-release matrix with a specified in vitro release profile.
• A lactose-free formulation with improved stability or reduced impurity formation.
• A unit-dose oral liquid with defined concentration and preservative system.
• A multiparticulate product with dose-proportional release.

The strongest protection is usually created by technical performance data, not by excipient naming alone.

What manufacturing and IP barriers affect commercial entry?

Manufacturing risk is concentrated in powder flow, segregation, tablet compression, coating uniformity, dissolution control, and scale-up reproducibility.

Immediate-release tablets

Direct compression may reduce cost, but high drug loading can produce poor flow and weight variation. Wet granulation can improve compressibility but adds processing time, residual-moisture risk, and stability requirements. Lubricant overmixing can reduce tablet wetting and slow dissolution.

Taste-masked products

Taste masking can create a dissolution tradeoff. A coating thick enough to prevent bitterness may delay release or create dose dumping risks if damaged. Coated particles also increase process complexity and may reduce drug loading.

Modified-release products

The key barrier is release reproducibility across manufacturing scale, food conditions, gastrointestinal pH, and alcohol exposure. The formulation must also demonstrate that the release profile produces a clinically acceptable exposure pattern.

Packaging

Moisture-sensitive ODTs and coated multiparticulates may require high-barrier blister packaging, desiccants, or unit-dose pouches. Packaging can materially affect cost of goods and channel suitability.

Which commercial opportunities are most attractive?

Opportunity	Development complexity	Differentiation	Commercial outlook
Low-cost conventional tablet	Low	Low	Viable only with manufacturing or supply advantage
Lactose-free tablet	Low to moderate	Moderate	Practical niche opportunity
Improved score-line and swallowability	Moderate	Moderate	Useful for adherence and patient handling
ODT or rapidly dispersing tablet	Moderate to high	High	Attractive if taste and dose load are solved
Oral solution	Moderate to high	High	Useful for dysphagia and titration markets
Modified-release product	High	High	Largest potential value, highest regulatory risk
Taste-masked multiparticulates	High	High	Potentially differentiated, but manufacturing-intensive
Institutional unit-dose packaging	Low to moderate	Moderate	Potential channel-specific opportunity

The best near-term strategy is usually a lactose-free, swallow-optimized immediate-release product with strong supply economics. The best higher-value strategy is a modified-release or taste-masked dosage form supported by pharmacokinetic and adherence data.

How does trazodone compare with competing antidepressant products?

Trazodone competes with generic selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, mirtazapine, doxepin, and sedating off-label sleep products. Its commercial position is shaped by low price, longstanding prescriber familiarity, flexible dosing, and sedative effects.

Product category	Excipient opportunity relative to trazodone
Generic SSRIs	Lower dose burden, but less opportunity for high-load formulation engineering
Mirtazapine ODT	Demonstrates commercial precedent for orally disintegrating antidepressant products
Doxepin	Lower-dose products may be easier to formulate as liquids or precision-dose products
Melatonin products	Strong taste and delivery differentiation, but different regulatory and clinical positioning
Trazodone	High-dose burden and bitterness create stronger formulation challenges and potentially larger differentiation space

Trazodone’s mature pricing limits the return from minor tablet changes. A differentiated product must either reduce administration friction, improve dose control, support a defined patient population, or create a clinically supported pharmacokinetic advantage.

What revenue exposure and launch scenarios should investors assess?

Revenue exposure for a new trazodone product is likely to come from share capture in a large generic market rather than protection of a premium brand price. Key variables are:

• Number of active generic competitors.
• Wholesale acquisition price.
• Payer substitution.
• Dosage-form convenience.
• Pharmacy stocking behavior.
• Manufacturing cost.
• FDA approval timing.
• Patent term and validity.
• Whether the product supports a new indication or only a new dosage form.

Scenario 1: Conventional generic launch

A company launches a standard immediate-release tablet. The product competes primarily on price, supply reliability, and wholesaler access. Patent risk is low, but gross margins are vulnerable to rapid price erosion.

Scenario 2: Differentiated immediate-release launch

The company markets a lactose-free, low-weight, score-optimized tablet. The product may obtain modest price and retention advantages, but the formulation must provide a clear purchasing rationale.

Scenario 3: Specialty dosage-form launch

An ODT, oral solution, or multiparticulate product targets dysphagia, geriatric care, or dose titration. The market is narrower, but substitution may be less automatic and the product may support improved pricing.

Scenario 4: Modified-release launch

A company develops once-daily or exposure-controlled trazodone. This scenario has the highest potential value but requires substantial clinical pharmacology, regulatory work, manufacturing validation, and patent investment.

What is the recommended excipient and IP strategy for Desyrel?

A staged strategy reduces risk:

1. Develop a lactose-free immediate-release platform using a robust direct-compression or dry-granulation process.
2. Benchmark disintegration, dissolution, hardness, friability, stability, and tablet mass against leading generics.
3. Evaluate crospovidone, sodium starch glycolate, mannitol, microcrystalline cellulose, and co-processed excipients.
4. Use film coating to improve swallowability and strength identification.
5. Develop a taste-masked multiparticulate or rapidly dispersing product as a higher-value extension.
6. Reserve modified release for a program with a clear pharmacokinetic or adherence hypothesis.
7. Build patent claims around measurable product performance and process control.
8. Use an ANDA strategy for true pharmaceutical equivalents and a 505(b)(2) strategy for materially differentiated dosage forms.
9. Confirm Orange Book listings and Paragraph IV exposure before finalizing the reference-product and claim strategy.
10. Protect scale-up parameters and coating processes as trade secrets where patent disclosure would create limited value.

Key Takeaways

• Desyrel and trazodone are mature products with broad generic competition.
• The active ingredient provides little basis for new exclusivity.
• Conventional excipient substitution is commercially useful mainly for cost, tolerability, lactose avoidance, and supply reliability.
• ODT, oral solution, taste-masked, and modified-release products offer stronger differentiation.
• High dose load, bitter taste, tablet burden, and sedation-related dose flexibility are the main formulation drivers.
• A new formulation may require an ANDA, 505(b)(2) application, or NDA depending on its release profile, dosage form, and labeling.
• Orange Book patents and Paragraph IV risk must be assessed product by product.
• Stronger patent protection requires defined formulation architecture, manufacturing parameters, dissolution performance, or clinical pharmacology data.
• The most practical near-term opportunity is a lactose-free, swallow-optimized immediate-release product.
• The highest-value opportunity is a clinically supported modified-release or taste-masked dosage form.

FAQs

Can lactose be removed from a generic Desyrel tablet?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or a co-processed filler. The finished product must still meet pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

Is trazodone suitable for an orally disintegrating tablet?

Trazodone is technically suitable, but the high dose and bitter taste create major development constraints. Taste-masked particles or multiparticulates may be more practical than placing the full dose in a small conventional ODT.

Does an excipient change create new patent protection?

Usually not by itself. Patent value depends on the claimed composition, excipient ratios, manufacturing process, release profile, stability result, or clinical effect. Routine substitution of one established filler for another is vulnerable to obviousness arguments.

Can a trazodone oral solution be approved through an ANDA?

Possibly, but the pathway depends on the reference product, dosage-form equivalence, formulation differences, and FDA’s applicable bioequivalence requirements. A materially different liquid product may require a 505(b)(2) application.

Is a modified-release trazodone product commercially attractive?

It can be, provided the product demonstrates a meaningful pharmacokinetic, adherence, dosing-frequency, or tolerability advantage. The development and regulatory burden is substantially higher than for a conventional immediate-release generic.

References

1. U.S. Food and Drug Administration. (n.d.). Desyrel (trazodone hydrochloride) prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (2022). 505(b)(2) applications. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2018). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2016). M13: Bioequivalence for immediate-release solid oral dosage forms. Center for Drug Evaluation and Research.